At trial termination on Oct @ , @ , cladribine was associated with a risk reduction versus placebo for time to conversion to clinically definite MS ( hazard ratio -LSB- HR -RSB- for @ mg/kg = @ , @ % CI @-@ @ , p < @ ; HR for @ mg/kg = @ , @-@ @ , p < @ ) .